Nexviadyme (Avalglucosidase Alfa)

Avalglucosidase alfa, the active ingredient in Nexviadyme, is an enzyme replacement therapy presented as an intravenous formulation for infusion use. It is indicated for the treatment of Pompe disease, a lysosomal storage disorder characterized by glycogen accumulation in muscle cells, and is administered under medical supervision to patients with confirmed diagnosis.

GNH USA supplies Nexviadyme as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and specialty clinics worldwide. The company adheres to stringent quality standards and provides cold‑chain logistics for biologic products.

Nexviadyme is an enzyme replacement therapy used in the management of Pompe disease and its clinical sub‑types.

- Infantile‑onset Pompe disease: improves motor development and survival rates. - Late‑onset Pompe disease: reduces respiratory decline and enhances exercise capacity. - Adult Pompe disease: supports muscle strength and functional endurance.

Nexviadyme may be associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects: - Infusion‑related reactions: flushing, chills, or fever. - Headache or mild dizziness. - Nausea or abdominal discomfort. - Elevated liver enzymes (transaminases).

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity. - Cardiac arrhythmias or conduction abnormalities. - Severe respiratory compromise during infusion.

Prior to initiating therapy, clinicians should evaluate patient history and monitor for potential risks.

- Baseline assessment: obtain liver function tests and cardiac evaluation. - Infusion monitoring: observe for signs of hypersensitivity during and after administration. - Concomitant conditions: use caution in patients with pre‑existing cardiac or respiratory disease. - Pregnancy and lactation: discuss potential risks with the prescriber; limited data are available. - Storage: Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Nexviadyme may interact with other agents that affect immune response or cardiac function.

Major Interactions (Avoid): - Live vaccines: may increase risk of infection. - Strong immunosuppressants: could diminish therapeutic efficacy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask infusion‑related tachycardia. - Antihistamines: may reduce severity of mild infusion reactions. - Other enzyme replacement products: assess cumulative immunogenic risk.